Search

Your search keyword '"Pacheco-Castro A"' showing total 125 results
Start Over Author "Pacheco-Castro A"
125 results on '"Pacheco-Castro A"'

102. Monologue or Intercultural Dialogue Between Medical Systems? An Educational Challenge for Medical Sciences

Author

Parra Beltrán, Leonardo, Pacheco Castro, Ana María, Parra Beltrán, Leonardo, and Pacheco Castro, Ana María

Abstract

Each medical cultural system constructs knowledge about health through specialization or interculturalism. The knowledge constructed through interculturalism has sought, mainly, to adapt the delivery of health care services to the users’ cultural referents. This emphasis has overlooked the opportunities embedded in the establishment of intercultural relationships between medical systems based on dialogue, especially in regard to the adjustment of the disciplinary boundaries of medical cultural systems that would allow the construction of new knowledge on health. This absence of dialogue has been determined by epistemological barriers inherent to every system as well as by social domination. This article presents some concepts related to cognition processes which encourage the reflection on the possibilities to overcome such barriers so that the health sciences may contribute to the effective implementation of the World Health Organization and the State’s recommendations on the matter., Cada sistema cultural médico construye conocimientos sobre la salud a partir de la especialización y del interculturalismo. El conocimiento construido a partir de las relaciones interculturales ha buscado, principalmente, adecuar la atención en salud a los referentes culturales de los usuarios. Este énfasis ha omitido las oportunidades que representa establecer relaciones entre sistemas culturales médicos basadas en el diálogo; especialmente, las que permitirían ajustar los límites disciplinares de los sistemas en relación, para construir nuevo conocimiento en salud. En esta ausencia de diálogo han incidido tanto las barreras epistemológicas propias de cada sistema, como las relaciones de dominación social. Este artículo expone algunos conceptos relacionados con los procesos cognoscitivos que posibilitan superar dichas barreras, con el fin de que las ciencias de la salud puedan aportar a la puesta en práctica de las recomendaciones de la Organización Mundial de la Salud y del Estado sobre el particular.

Published
2010

103. Signaling through a CD3 gamma-deficient TCR/CD3 complex in immortalized mature CD4+ and CD8+ T lymphocytes

Author

Pacheco-Castro A, Alvarez-Zapata D, Serrano-Torres P, and Jose Regueiro

Subjects
CD4-Positive T-Lymphocytes, Tumor Necrosis Factor-alpha, Cell Differentiation, Receptors, Antigen, T-Cell, gamma-delta, CD8-Positive T-Lymphocytes, Lymphocyte Activation, Herpesvirus 2, Saimiriine, Immunophenotyping, Receptor-CD3 Complex, Antigen, T-Cell, Humans, Interleukin-2, Tetradecanoylphorbol Acetate, Cell Line, Transformed, Signal Transduction
Abstract

The biologic role of each CD3 chain and their relative contribution to the signals transduced through the TCR/CD3 complex and to downstream activation events are still controversial: they may be specialized or redundant. We have immortalized peripheral blood CD4+ and CD8+ T lymphocytes from a human selective CD3 gamma deficiency using Herpesvirus saimiri. The accessibility of the mutant TCR/CD3 complex to different Abs was consistently lower in immortalized CD8+ cells when compared with CD4+ cells, relative to their corresponding CD3 gamma-sufficient controls. Several TCR/CD3-induced downstream activation events, immediate (calcium flux), early (cytotoxicity and induction of surface CD69 or CD40L activation markers or intracellular TNF-alpha) and late (proliferation and secretion of TNF-alpha), were normal in gamma-deficient cells, despite the fact that their TCR/CD3 complexes were significantly less accessible than those of controls. In contrast, the accumulation of intracellular IL-2 or its secretion after CD3 triggering was severely impaired in gamma-deficient cells. The defect was upstream of protein kinase C activation because addition of transmembrane stimuli (PMA plus calcium ionophore) completely restored IL-2 secretion in gamma-deficient cells. These results suggest that the propagation of signals initiated at the TCR itself can result in a modified downstream signaling cascade with distinct functional consequences when gamma is absent. They also provide evidence for the specific participation of the CD3 gamma chain in the induction of certain cytokine genes in both CD4+ and CD8+ human mature T cells. These immortalized mutant cells may prove to be useful in isolating cytosolic signaling pathways emanating from the TCR/CD3 complex.

Published
1998

104. Herpesvirus saimiri immortalization of alpha beta and gamma delta human T-lineage cells derived from CD34+ intrathymic precursors in vitro

Author

Pacheco-Castro A, Márquez C, Ml, Toribio, Almudena R Ramiro, Trigueros C, and Jr, Regueiro

Subjects
Cell Transformation, Neoplastic, T-Lymphocyte Subsets, Child, Preschool, Interleukin-7, Receptors, Antigen, T-Cell, alpha-beta, Interleukin-8, Humans, Infant, Antigens, CD34, Receptors, Antigen, T-Cell, gamma-delta, Thymus Gland, Hematopoietic Stem Cells, Herpesvirus 2, Saimiriine
Abstract

Herpesvirus saimiri (HVS), an agent that can infect many human cell types, has been shown to immortalize selectively TCR alpha beta + CD3+ T lymphocytes. Human T cell precursors defined as CD34+CD3-CD4-CD8- were isolated from thymic samples and exposed to HVS in the presence of either IL-2 or IL-7. Cultures lacking the virus were non-viable by day 15. Test cultures, in contrast, showed a sustained proliferative activity lasting5 months, allowing the phenotypical and molecular analysis of the cellular progeny. In the presence of IL-7, TCR alpha beta + cells with three different phenotypes (mainly CD4+CD8-, but also CD4+CD8+ and CD4-CD8+) were immortalized, whereas no TCR gamma delta + cells were recovered. Kinetic studies showed that the expansion of immortalized TCR alpha beta + cells was preceded by a gradual loss of CD34+ cells followed by a transient accumulation of two distinct cell subsets: first CD1+CD4+CD3- cells and then CD4+CD8+ thymocytes. This resembles early phenotypic changes occurring during normal intrathymic T cell development. In the presence of IL-2, in contrast, only TCR gamma delta + cells were immortalized (mainly CD4-CD8+, but also CD4-CD8-). The results show that HVS can be used to read the CD3+ cellular outcome of T cell differentiation assays, including gamma delta + CD4-CD8+, gamma delta + CD4-CD8-, alpha beta + CD4+CD8-, alpha beta + CD4-CD8+ and alpha beta + CD4+CD8+ T cells. A clear role for different cytokines (IL-2 for gamma delta + cells, IL-7 for alpha beta + cells) in early T cell commitment was also apparent.

Published
1996

105. ANDROLOGY

Author

Hu, J. C. Y., primary, Seo, B. K., additional, Neri, Q. V., additional, Rozenwaks, Z., additional, Palermo, G. D., additional, Fields, T., additional, Monahan, D., additional, Rosenwaks, Z., additional, Szkodziak, P., additional, Plewka, K., additional, Wozniak, S., additional, Czuczwar, P., additional, Mroczkowski, A., additional, Lorenzo Leon, C., additional, Hernandez, J., additional, Chinea Mendez, E., additional, Concepcion Lorenzo, C., additional, Sanabria Perez, V., additional, Puopolo, M., additional, Palumbo, A., additional, Toth, B., additional, Franz, C., additional, Montag, M., additional, Boing, A., additional, Strowitzki, T., additional, Nieuwland, R., additional, Griesinger, G., additional, Schultze-Mosgau, A., additional, Cordes, T., additional, Depenbusch, M., additional, Diedrich, K., additional, Vloeberghs, V., additional, Verheyen, G., additional, Camus, M., additional, Van de Velde, H., additional, Goossens, A., additional, Tournaye, H., additional, Coppola, G., additional, Di Caprio, G., additional, Wilding, M., additional, Ferraro, P., additional, Esposito, G., additional, Di Matteo, L., additional, Dale, R., additional, Dale, B., additional, Daoud, S., additional, Auger, J., additional, Wolf, J. P., additional, Dulioust, E., additional, Lafuente, R., additional, Lopez, G., additional, Brassesco, M., additional, Hamad, M., additional, Montenarh, M., additional, Hammadeh, M., additional, Robles, F., additional, Magli, M. C., additional, Crippa, A., additional, Pescatori, E., additional, Ferraretti, A. P., additional, Gianaroli, L., additional, Zahiri, M., additional, Movahedin, M., additional, Mowla, S. J., additional, Noruzinia, M., additional, Crivello, A. M., additional, Sermondade, N., additional, Dupont, C., additional, Hafhouf, E., additional, Cedrin-Durnerin, I., additional, Poncelet, C., additional, Benzacken, B., additional, Levy, R., additional, Sifer, C., additional, Ferfouri, F., additional, Boitrelle, F., additional, Clement, P., additional, Molina Gomes, D., additional, Bailly, M., additional, Selva, J., additional, Vialard, F., additional, Yaprak, E., additional, Basar, M., additional, Guzel, E., additional, Arda, O., additional, Irez, T., additional, Norambuena, P., additional, Krenkova, P., additional, Tuettelmann, F., additional, Kliesch, S., additional, Paulasova, P., additional, Stambergova, A., additional, Macek, M., additional, Rivera, R., additional, Garrido-Gomez, T., additional, Galletero, S., additional, Meseguer, M., additional, Dominguez, F., additional, Garrido, N., additional, Mallidis, C., additional, Sanchez, V., additional, Weigeng, L., additional, Redmann, K., additional, Wistuba, J., additional, Gross, P., additional, Wuebbelling, F., additional, Fallnich, C., additional, Burger, M., additional, Schlatt, S., additional, San Celestino Carchenilla, M., additional, Pacheco Castro, A., additional, Simon Sanjurjo, P., additional, Molinero Ballesteros, A., additional, Rubio Garcia, S., additional, Garcia Velasco, J. A., additional, Macanovic, B., additional, Otasevic, V., additional, Korac, A., additional, Vucetic, M., additional, Garalejic, E., additional, Ivanovic Burmazovic, I., additional, Filipovic, M. R., additional, Buzadzic, B., additional, Stancic, A., additional, Jankovic, A., additional, Velickovic, K., additional, Golic, I., additional, Markelic, M., additional, Korac, B., additional, Gosalvez, J., additional, Ruiz-Jorro, M., additional, Garcia-Ochoa, C., additional, Sachez-Martin, P., additional, Martinez-Moya, M., additional, Caballero, P., additional, Hasegawa, N., additional, Fukunaga, N., additional, Nagai, R., additional, Kitasaka, H., additional, Yoshimura, T., additional, Tamura, F., additional, Kato, M., additional, Nakayama, K., additional, Oono, H., additional, Kojima, E., additional, Yasue, K., additional, Watanabe, H., additional, Asano, E., additional, Hashiba, Y., additional, Asada, Y., additional, Das, M., additional, Al-Hathal, N., additional, San-Gabriel, M., additional, Phillips, S., additional, Kadoch, I. J., additional, Bissonnette, F., additional, Holzer, H., additional, Zini, A., additional, Zebitay, A. G., additional, Ocal, P., additional, Sahmay, S., additional, Karahuseyinoglu, S., additional, Usta, T., additional, Repping, S., additional, Silber, S., additional, Van Wely, M., additional, Datta, A., additional, Nayini, K., additional, Eapen, A., additional, Barlow, S., additional, Lockwood, G., additional, Tavares, R., additional, Baptista, M., additional, Publicover, S. J., additional, Ramalho-Santos, J., additional, Vaamonde, D., additional, Rodriguez, I., additional, Diaz, A., additional, Darr, C., additional, Chow, V., additional, Ma, S., additional, Smith, R., additional, Jeria, F., additional, Rivera, J., additional, Gabler, F., additional, Nicolai, H., additional, Cunha, M., additional, Viana, P., additional, Goncalves, A., additional, Silva, J., additional, Oliveira, C., additional, Teixeira da Silva, J., additional, Ferraz, L., additional, Madureira, C., additional, Doria, S., additional, Sousa, M., additional, Barros, A., additional, Herrero, M. B., additional, Delbes, G., additional, Troueng, E., additional, Chan, P. T. K., additional, Vingris, L., additional, Setti, A. S., additional, Braga, D. P. A. F., additional, Figueira, R. C. S., additional, Iaconelli, A., additional, Borges, E., additional, Sargin Oruc, A., additional, Gulerman, C., additional, Zeyrek, T., additional, Yilmaz, N., additional, Tuzcuoglu, D., additional, Cicek, N., additional, Scarselli, F., additional, Terribile, M., additional, Franco, G., additional, Zavaglia, D., additional, Dente, D., additional, Zazzaro, V., additional, Riccio, T., additional, Minasi, M. G., additional, Greco, E., additional, Cejudo-Roman, A., additional, Ravina, C. G., additional, Candenas, L., additional, Gallardo-Castro, M., additional, Martin-Lozano, D., additional, Fernandez-Sanchez, M., additional, Pinto, F. M., additional, Balasuriya, A., additional, Serhal, P., additional, Doshi, A., additional, Harper, J., additional, Romany, L., additional, Fernandez, J. L., additional, Pellicer, A., additional, Ribas-Maynou, J., additional, Garcia-Peiro, A., additional, Fernandez-Encinas, A., additional, Prada, E., additional, Jorda, I., additional, Cortes, P., additional, Llagostera, M., additional, Navarro, J., additional, Benet, J., additional, Kesici, H., additional, Cayli, S., additional, Erdemir, F., additional, Karaca, Z., additional, Aslan, H., additional, Ocakli, S., additional, Tas, U., additional, Ozdemir, A. A., additional, Aktas, R. G., additional, Tok, O. E., additional, Li, S., additional, Lu, C., additional, Hwu, Y., additional, Lee, R. K., additional, Landaburu, I., additional, Gonzalvo, M. C., additional, Clavero, A., additional, Ramirez, J. P., additional, Pedrinaci, S., additional, Serrano, M., additional, Montero, L., additional, Carrillo, S., additional, Weiss, J., additional, Ortiz, A. P., additional, Castilla, J. A., additional, Sahin, O., additional, Bakircioglu, E., additional, Serdarogullari, M., additional, Bayram, A., additional, Yayla, S., additional, Ulug, U., additional, Tosun, S. B., additional, Bahceci, M., additional, Yoon, S. Y., additional, Shin, D. H., additional, Shin, T. E., additional, Park, E. A., additional, Won, H. J., additional, Kim, Y. S., additional, Lee, W. S., additional, Yoon, T. K., additional, Lee, D. R., additional, Hattori, H., additional, Nakajo, Y., additional, Kyoya, T., additional, Kuchiki, M., additional, Kanto, S., additional, Kyono, K., additional, Park, M., additional, Park, M. R., additional, Lim, E. J., additional, Choi, Y., additional, Mitra, A., additional, Bhattacharya, J., additional, Kundu, A., additional, Mukhopadhaya, D., additional, Pal, M., additional, Enciso, M., additional, Alfarawati, S., additional, Wells, D., additional, Abad, C., additional, Amengual, M. J., additional, Esmaeili, V., additional, Safiri, M., additional, Shahverdi, A. H., additional, Alizadeh, A. R., additional, Ebrahimi, B., additional, Brucculeri, A. M., additional, Ruvolo, G., additional, Giovannelli, L., additional, Schillaci, R., additional, Cittadini, E., additional, Scaravelli, G., additional, Perino, A., additional, Cortes Gallego, S., additional, Gabriel Segovia, A., additional, Nunez Calonge, R., additional, Guijarro Ponce, A., additional, Ortega Lopez, L., additional, Caballero Peregrin, P., additional, Heindryckx, B., additional, Kashir, J., additional, Jones, C., additional, Mounce, G., additional, Ramadan, W. M., additional, Lemmon, B., additional, De Sutter, P., additional, Parrington, J., additional, Turner, K., additional, Child, T., additional, McVeigh, E., additional, Coward, K., additional, Tosun, S., additional, Ciray, N., additional, Saeidi, S., additional, Shapouri, F., additional, Hoseinifar, H., additional, Sabbaghian, M., additional, Pacey, A., additional, Aflatoonian, R., additional, Bosco, L., additional, Carrillo, L., additional, Pane, A., additional, Manno, M., additional, Roccheri, M. C., additional, Selles, E., additional, Garcia-Herrero, S., additional, Martinez, J. A., additional, Munoz, M., additional, Durmaz, A., additional, Dikmen, N., additional, Gunduz, C., additional, Tavmergen Goker, E., additional, Tavmergen, E., additional, Gozuacik, D., additional, Vatansever, H. S., additional, Kara, B., additional, Calimlioglu, N., additional, Yasar, P., additional, Semerci, B., additional, Baka, M., additional, Ozbilgin, K., additional, Karabulut, A., additional, Tekin, A., additional, Sabah, B., additional, Cottin, V., additional, Kottelat, D., additional, Fellmann, M., additional, Halm, S., additional, Rosenthaler, E., additional, Kisida, T., additional, Kojima, F., additional, Sakamoto, T., additional, Makutina, V. A., additional, Balezin, S. L., additional, Rosly, O. F., additional, Slishkina, T. V., additional, Hatzi, E., additional, Lazaros, L., additional, Xita, N., additional, Makrydimas, G., additional, Sofikitis, N., additional, Kaponis, A., additional, Stefos, T., additional, Zikopoulos, K., additional, Georgiou, I., additional, Hibi, H., additional, Ohori, T., additional, Sumitomo, M., additional, Anarte, C., additional, Calvo, I., additional, Domingo, A., additional, Presilla, N., additional, Aleman, M., additional, Bou, R., additional, Guardiola, F., additional, Agirregoikoa, J. A., additional, De Pablo, J. L., additional, Barrenetxea, G., additional, Zhylkova, I., additional, Feskov, O., additional, Feskova, I., additional, Zozulina, O., additional, Somova, O., additional, Nabi, A., additional, Khalili, M. A., additional, Roudbari, F., additional, Parmegiani, L., additional, Cognigni, G. E., additional, Bernardi, S., additional, Taraborrelli, S., additional, Troilo, E., additional, Ciampaglia, W., additional, Pocognoli, P., additional, Infante, F. E., additional, Tabarelli de fatis, C., additional, Arnone, A., additional, Maccarini, A. M., additional, Filicori, M., additional, Silva, L., additional, Oliveira, J. B. A., additional, Petersen, C. G., additional, Mauri, A. L., additional, Massaro, F. C., additional, Cavagna, M., additional, Baruffi, R. L. R., additional, Franco, J. G., additional, Fujii, Y., additional, Endou, Y., additional, Mtoyama, H., additional, Shokri, S., additional, and Aitken, R. J., additional

Published
2012
Full Text
View/download PDF

107. Toward gene therapy for human CD3 deficiencies

Author

Pacheco Castro, A., Martín Fernández, J.M., Millán, R., Sanal, O., Allende Martínez, Luis Miguel, Regueiro González-Barros, José Ramón, Pacheco Castro, A., Martín Fernández, J.M., Millán, R., Sanal, O., Allende Martínez, Luis Miguel, and Regueiro González-Barros, José Ramón

Abstract

Depto. de Inmunología, Oftalmología y ORL, Fac. de Medicina, TRUE, pub

Published
2003

108. Andrology (Male Fertility, Spermatogenesis)

Author

Matsumoto, Y., primary, Goto, S., additional, Hashimoto, H., additional, Kokeguchi, S., additional, Shiotani, M., additional, Okada, H., additional, Cohen - Bacrie, P., additional, Hazout, A., additional, Belloc, S., additional, De Mouzon, J., additional, Menezo, Y., additional, Dumont, M., additional, Junca, A. M., additional, Cohen-Bacrie, M., additional, Alvarez, S., additional, Olivennes, F., additional, Prisant, N., additional, Weltin, M., additional, Geissler, W., additional, Clussmann, C., additional, Strowitzki, T., additional, Eggert-Kruse, W., additional, Endou, Y., additional, Fjii, Y., additional, Motoyama, H., additional, Quintana, F. Q., additional, Zaloa Larreategui, Z. L., additional, Iratxe Penalba, I. P., additional, Sara Ortega, S. O., additional, Monica Martin, M. M., additional, Guillermo Quea, G. Q., additional, Jose Serna, J. S., additional, Showell, M. G., additional, Brown, J., additional, Yazdani, A., additional, Stankiewicz, M. T., additional, Hart, R. J., additional, Zumoffen, C., additional, Munuce, M. J., additional, Caille, A., additional, Ghersevich, S., additional, Lendinez, A. M., additional, Perez-Nevot, B., additional, Palomares, A. R., additional, Serrano Garballo, A., additional, Rodriguez, A., additional, Reche, A., additional, Mayor-Olea, A., additional, Ruiz-Galdon, M., additional, Reyes-Engel, A., additional, Mendiola, J., additional, Jorgensen, N., additional, Andersson, A. M., additional, Calafat, A. M., additional, Redmon, J. B., additional, Drobnis, E. Z., additional, Wang, C., additional, Sparks, A., additional, Thurston, S. W., additional, Liu, F., additional, Swan, S. H., additional, Tarasconi, A. C., additional, Tarasconi, B. V., additional, Tarasconi, D. V., additional, Silva, E. M. V., additional, Fujii, Y., additional, Crha, I., additional, Pribyl, J., additional, Skladal, P., additional, Zakova, J., additional, Ventruba, P., additional, Pohanka, M., additional, De La Fuente, G., additional, Pacheco, A., additional, Velasco, J. A. G., additional, Requena, A., additional, Pacheco Castro, A., additional, San Celestino Carchenilla, M., additional, Salvanes, R., additional, Arnanz, A., additional, Balmori, C., additional, Pellicer, A., additional, Garcia-Velasco, J. A., additional, Ishikawa, T., additional, Fujisawa, M., additional, Kranz, S., additional, Hersemeyer, K., additional, Hentrich, A., additional, Tinneberg, H. R., additional, Konrad, L., additional, Simon, L., additional, Lutton, D., additional, McManus, J., additional, Lewis, S. E. M., additional, Rubio, S., additional, Simon Sanjurjo, P., additional, Lewis, S., additional, Buzzi, J., additional, Valcarcel, A., additional, Lombardi, E., additional, Oses, R., additional, Rawe, V., additional, Young, E., additional, Magendzo, A., additional, Lizama, S., additional, Duque, G., additional, Mackenna, A., additional, Monqaut, A., additional, Zavaleta, C., additional, Lopez, G., additional, Lafuente, R., additional, Brassesco, M., additional, Condorelli, R., additional, La Vignera, S., additional, La Rosa, S., additional, Barone, N., additional, Vicari, E., additional, Bellanca, S., additional, D'Agata, R., additional, Calogero, A. E., additional, Enciso, M., additional, Iglesias, M., additional, Galan, I., additional, Gosalvez, A., additional, Gosalvez, J., additional, Curaba, M., additional, Poels, J., additional, Van Langendonckt, A., additional, Donnez, J., additional, Wyns, C., additional, Garcez, M., additional, Salvador, M., additional, Pasqualotto, E. B., additional, Braga, D. P. A. F., additional, Borges, E., additional, Pasqualotto, F. F., additional, Aoki, T., additional, Figueira, R. C. S., additional, Maldonado, L. G. L., additional, Iaconelli, A., additional, Frassini, R., additional, Mandelli, J., additional, Setti, A. S., additional, Cortezzi, S. S., additional, Di Mauro, M., additional, Burrello, N., additional, Kashir, J., additional, Jones, C., additional, Young, C., additional, Ruas, M., additional, Grasa, P., additional, Rietdorf, K., additional, Heytens, E., additional, Heindryckx, B., additional, Yoon, S. Y., additional, Fissore, R. A., additional, Deane, C. M., additional, Nikiforaki, D., additional, Tee, S. T., additional, de Sutter, P., additional, Parrington, J., additional, Coward, K., additional, Visser, L., additional, Westerveld, G. H., additional, van Daalen, S. K. M., additional, van der Veen, F., additional, Lombardi, M. P., additional, Repping, S., additional, Cubillos, S., additional, Sanchez, S., additional, Pedraza, J., additional, Charria, G., additional, Aparicio, H., additional, Gongora, A., additional, Caldino, F., additional, Cuneo, S., additional, Ou, J. P., additional, Zhao, W. E., additional, Liu, Y. F., additional, Xu, Y. W., additional, Zhou, C. Q., additional, Al-Asmar Pinar, N., additional, Peinado, V., additional, Gruhn, J., additional, Susiarjo, M., additional, Gil-Salom, M., additional, Martinez-Jabaloyas, J. M., additional, Remohi, J., additional, Rubio, C., additional, Hassold, T., additional, Al-Asmar, N., additional, Rodrigo, L., additional, Hassold, T. J., additional, Bungum, M., additional, Forsell, N., additional, Giwercman, A., additional, Amiri, I., additional, Sheikh, N., additional, Najafi, R., additional, Godarzi, M., additional, Farimani, M., additional, Makukh, H., additional, Tyrkus, M., additional, Zastavna, D., additional, Nakonechnuy, A., additional, Khayat, S. S., additional, Schileiko, L. V., additional, Kurilo, L. F., additional, Garcia-Herrero, S., additional, Garrido, N., additional, Martinez-Conejero, J. A., additional, Romany, L., additional, Meseguer, M., additional, Dorphin, B., additional, Lefevre, M., additional, Gout, C., additional, Oger, P., additional, Yazbeck, C., additional, Rougier, N., additional, De Stefani, S., additional, Scala, V., additional, Benedetti, S., additional, Tagliamonte, M. C., additional, Zavagnini, E., additional, Palini, S., additional, Bulletti, C., additional, Canestrari, F., additional, Subiran, N., additional, Pinto, F. M., additional, Candenas, M. L., additional, Agirregoitia, E., additional, Irazusta, J., additional, Cha, E. M., additional, Lee, J. H., additional, Park, I. H., additional, Lee, K. H., additional, Kim, M. H., additional, Jensen, M. S., additional, Rebordosa, C., additional, Thulstrup, A. M., additional, Toft, G., additional, Sorensen, H. T., additional, Bonde, J. P., additional, Henriksen, T. B., additional, Olsen, J., additional, Bosco, L., additional, Speciale, M., additional, Manno, M., additional, Amireh, N., additional, Roccheri, M. C., additional, Cittadini, E., additional, Wu, P., additional, Lee, Y. M., additional, Chen, H. W., additional, Tzeng, C. R., additional, Llacer, J., additional, Ten, J., additional, Lledo, B., additional, Rodriguez-Arnedo, A., additional, Morales, R., additional, Bernabeu, R., additional, Garcia-Peiro, A., additional, Martinez-Heredia, J., additional, Oliver-Bonet, M., additional, Ribas, J., additional, Abad, C., additional, Amengual, M. J., additional, Navarro, J., additional, Benet, J., additional, Moutou, C., additional, Gardes, N., additional, Nicod, J. C., additional, Becker, N., additional, Bailly, M. P., additional, Galland, I., additional, Pirello, O., additional, Rongieres, C., additional, Wittemer, C., additional, Viville, S., additional, Elmahaishi, W., additional, Smith, B., additional, Doshi, A., additional, Serhal, P., additional, Harper, J. C., additional, Rennemeier, C., additional, Kammerer, U., additional, Dietl, J., additional, Staib, P., additional, Elgmati, K., additional, Nomikos, M., additional, Theodoridou, M., additional, Calver, B., additional, Swann, K., additional, Lai, F. A., additional, Georgiou, I., additional, Lazaros, L., additional, Xita, N., additional, Kaponis, A., additional, Plachouras, N., additional, Hatzi, E., additional, Zikopoulos, K., additional, Ferfouri, F., additional, Clement, P., additional, Molina Gomes, D., additional, Albert, M., additional, Bailly, M., additional, Wainer, R., additional, Selva, J., additional, Vialard, F., additional, Takisawa, T., additional, Usui, K., additional, Kyoya, T., additional, Shibuya, Y., additional, Hattori, H., additional, Sato, Y., additional, Ota, M., additional, Kyono, K., additional, Chiu, P. C., additional, Lam, K. K., additional, Lee, C. L., additional, Chung, M. K., additional, Huang, V. W., additional, O, W. S., additional, Tang, F., additional, Ho, P. C., additional, Yeung, W. S., additional, Kim, C. H., additional, Lee, J. Y., additional, Kim, S. H., additional, Suh, C. S., additional, Shin, Y. K., additional, Kang, Y. J., additional, Jung, J. H., additional, Cha, C. Y., additional, Hwang, E. S., additional, Mukaida, T., additional, Nagaba, M., additional, Takahashi, K., additional, Elkaffash, D., additional, Sedrak, M., additional, Huhtaniemi, I., additional, Abdel-Al, T., additional, Younan, D., additional, Cassuto, N. G., additional, Bouret, D., additional, Hammoud, I., additional, Barak, Y., additional, Seshadri, S., additional, Bates, M., additional, Vince, G., additional, Jones, D. I., additional, Ben Khalifa, M., additional, Montjean, D., additional, Cohen-Bacrie, P., additional, Aubriot, F. X., additional, Cohen, M., additional, Boudjema, E., additional, Magli, M. C., additional, Crippa, A., additional, Baccetti, B., additional, Ferraretti, A. P., additional, Gianaroli, L., additional, Singer, T., additional, Neri, Q. V., additional, Hu, J. C., additional, Maggiulli, R., additional, Kollman, Z., additional, Rauch, E., additional, Schlegel, P. N., additional, Rosenwaks, Z., additional, Palermo, G. D., additional, Zorn, B., additional, Skrbinc, B., additional, Matos, E., additional, Golob, B., additional, Pfeifer, M., additional, Osredkar, J., additional, Sabanegh, E., additional, Sharma, R. K., additional, Thiyagarajan, A., additional, Agarwal, A., additional, Robin, G., additional, Boitrelle, F., additional, Marcelli, F., additional, Marchetti, C., additional, Mitchell, V., additional, Dewailly, D., additional, Rigot, J. M., additional, Rives, N., additional, Perdrix, A., additional, Travers, A., additional, Milazzo, J. P., additional, Mousset-Simeon, N., additional, Mace, B., additional, Jakab, A., additional, Molnar, Z., additional, Benyo, M., additional, Levai, I., additional, Kassai, Z., additional, Ihan, A., additional, Kopitar, A., additional, Kolbezen, M., additional, Vaamonde, D., additional, Da Silva-Grigoletto, M. E., additional, Garcia-Manso, J. M., additional, Vaamonde-Lemos, R., additional, Oehninger, S. C., additional, Walis, G., additional, Monahan, D., additional, Ermolovich, E., additional, Fadlon, E., additional, Abu Elhija, A., additional, Abu Elhija, M., additional, Lunenfeld, E., additional, Huleihel, M., additional, Costantini-Ferrando, M., additional, Hu, J. C. Y., additional, Alvarez, J. G., additional, Velilla, E., additional, Lopez-Teijon, M., additional, Lopez-Fernandez, C., additional, Tempest, H. G., additional, Sun, F., additional, Ko, E., additional, Turek, P., additional, Martin, R. H., additional, Zomeno-Abellan, M. T., additional, Ramirez, A., additional, Gutierrez-Adan, A., additional, Martinez, J. C., additional, Landeras, J., additional, Ballesta, J., additional, Aviles, M., additional, Ganaiem, M., additional, Binder, S., additional, Meinhardt, A., additional, Sousa, L., additional, Grangeia, A., additional, Carvalho, F., additional, Sousa, M., additional, Barros, A., additional, Sifer, C., additional, Sermondade, N., additional, Hafhouf, E., additional, Poncelet, C., additional, Benzacken, B., additional, Levy, R., additional, Wolf, J. P., additional, Crisol, L., additional, Aspichueta, F., additional, Hernandez, M. L., additional, Exposito, A., additional, Matorras, R., additional, Ruiz-Larrea, M. B., additional, Ruiz-Sanz, J. I., additional, Jallad, S., additional, Atig, F., additional, Ben Amor, H., additional, Saad, A. L. I., additional, Kerkeni, A., additional, Ajina, M., additional, Othmane, A. L. I., additional, Koscinski, I., additional, Ladureau, L., additional, Scarselli, F., additional, Casciani, V., additional, Lobascio, M., additional, Minasi, M. G., additional, Rubino, P., additional, Colasante, A., additional, Arizzi, L., additional, Litwicka, K., additional, Iammarrone, E., additional, Ferrero, S., additional, Mencacci, C., additional, Franco, G., additional, Zavaglia, D., additional, Nagy, Z. P., additional, Greco, E., additional, Ohgi, S., additional, Takahashi, M., additional, Kishi, C., additional, Suga, K., additional, Yanaihara, A., additional, Chamley, L. W., additional, Wagner, A., additional, and Shelling, A. N., additional

Published
2010
Full Text
View/download PDF

110. This title is unavailable for guests, please login to see more information.

Author

Zapata, David A., Pacheco Castro, Alberto, Torres, Pilar S., Ramiro, Almudena R., San José, Ester, Alarcón, Balbino, Alibaud, Laeticia, Rubin, Bent, Toribio, María L., Regueiro González-Barros, José Ramón, Zapata, David A., Pacheco Castro, Alberto, Torres, Pilar S., Ramiro, Almudena R., San José, Ester, Alarcón, Balbino, Alibaud, Laeticia, Rubin, Bent, Toribio, María L., and Regueiro González-Barros, José Ramón

Abstract

Mature CD4(+) and CD8(+) T lymphocytes are believed to build and express essentially identical surface alphabeta T-cell receptor-CD3 (TCR.CD3) complexes. However, TCR.CD3 expression has been shown to be more impaired in CD8(+) cells than in CD4(+) cells when CD3gamma is absent in humans or mice. We have addressed this paradox by performing a detailed phenotypical and biochemical analysis of the TCR.CD3 complex in human CD3gamma-deficient CD8(+) and CD4(+) T cells. The results indicated that the membrane TCR.CD3 complex of CD8(+) T lymphocytes was conformationally different from that of CD4(+) lymphocytes in the absence of CD3gamma. In addition, CD8(+), but not CD4(+), CD3gamma-deficient T lymphocytes were shown to contain abnormally glycosylated TCRbeta proteins, together with a smaller, abnormal TCR chain (probably incompletely processed TCRalpha). These results suggest the existence of hitherto unrecognized biochemical differences between mature CD4(+) and CD8(+) T lymphocytes in the intracellular control of alphabetaTCR. CD3 assembly, maturation, or transport that are revealed when CD3gamma is absent. Such lineage-specific differences may be important in receptor-coreceptor interactions during antigen recognition., Ministerio de Educación y Cultura (España), Comunidad Autónoma de Madrid, Comisión Interministerial de Ciencia y Tecnología (España), Dirección General de Ensenanza Superior e Investigación Científica (España), Ministerio de Educación y Cultura (España), Depto. de Inmunología, Oftalmología y ORL, Fac. de Medicina, TRUE, pub

Published
1999

114. CD3 IMMUNODEFICIENCIES

Author

Zapata, David A., primary, Pacheco-Castro, Alberto, additional, Torres, Pilar S., additional, Millán, Ruth, additional, and Regueiro, José R., additional

Published
2000
Full Text
View/download PDF

115. Conformational and Biochemical Differences in the TCR·CD3 Complex of CD8+ Versus CD4+ Mature Lymphocytes Revealed in the Absence of CD3γ

Author

Zapata, David A., primary, Pacheco-Castro, Alberto, additional, Torres, Pilar S., additional, Ramiro, Almudena R., additional, San José, Ester, additional, Alarcón, Balbino, additional, Alibaud, Laeticia, additional, Rubin, Bent, additional, Toribio, Marı́a L., additional, and Regueiro, José R., additional

Published
1999
Full Text
View/download PDF

119. Colaboradores

Author

Arias Navalón, José Antonio, Bollada, María Bringas, Jiménez Blanco, María Aránzazu, Laguna Martínez, José Julio, Olazabal Olarreaga, Isabel, and Pacheco Castro, Alberto

Published
2018
Full Text
View/download PDF

120. Contribution of CD3 gamma to TCR regulation and signaling in human mature T lymphocytes.

Author

Torres, Pilar S, Zapata, David A, Pacheco-Castro, Alberto, Rodríguez-Fernández, José L, Cabañas, Carlos, and Regueiro, José R

Abstract

CD3 proteins may have redundant as well as specific contributions to the intracellular propagation and final effector responses of TCR-mediated signals at different checkpoints during T cell differentiation. We report here on the participation of CD3 gamma in the activation and effector function of human mature T lymphocytes at the antigen recognition checkpoint. Following TCR-CD3 engagement of human CD3 gamma-deficient T cell lines, and despite their lower TCR-CD3 surface levels compared to normal controls, mature T cell responses such as protein tyrosine phosphorylation and the regulation of expression of several cell surface molecules, including the TCR-CD3 itself, were either normal or only slightly affected. In contrast, other physiological responses like the specific adhesion and concomitant cell polarization on ICAM-1-coated dishes were selectively defective, and activation-induced cell death was increased. Our data indicate that CD3 gamma contributes essential specialized signaling functions to certain mature T cell responses. Failure to generate appropriate interactions may abort cytoskeleton reorganization and initiate an apoptotic response.

Published
2002
Full Text
View/download PDF

121. Membrane and transmembrane signaling in Herpesvirus saimiri-transformed human CD4<SUP>+</SUP> and CD8<SUP>+</SUP> T lymphocytes is ATM-independent.

Author

Porras, O., Gatti, R.A., Rivero-Carmena, M., Pelaez, B., Pacheco-Castro, A., and Regueiro, J.R.

Abstract

In the genetic disorder ataxia telangiectasia (AT), humoral (B) and cellular (T) immunological abnormalities are frequently observed. As a consequence, AT patients are predisposed to life-threatening sinopulmonary infections. The pathogenic mechanisms remain unknown, but a role for ATM in signal transduction from membrane receptors has been proposed. We have explored the effects of a defective ATMgene on isolated human T-lineage cells from 13 AT patients with proven T cell dysfunction by transforming their CD4+ and CD8+ T lymphocytes with Herpesvirus saimiri, and analyzing their signaling behavior as compared to normal controls. Several functional parameters were assayed in response to both membrane (anti-CD3 and IL-2) and transmembrane (phorbol myristate acetate plus the calcium ionophore ionomycin) stimuli: (i) calcium mobilization, (ii) induction of activation molecules (CD25, CD40 ligand, CD69 and CD71), (iii) cytokine synthesis (IL-2 and tumor necrosis factor-α) and (iv) proliferation. All these early and late activation events were found to be normal in the transformed ATM-/-T cells, indicating that ATM is not necessary for their induction. As expected, ATM-/- transformed T cells showed an increased radiosensitivity by both radioresistant DNA synthesis and cell survival assays. In contrast to an earlier report testing transformed B lymphocytes, our results indicate that transformed mature peripheral T lymphocytes from AT patients do not have intrinsic immune function defects. Rather, the described T-lineage signaling impairments observed in patients may be secondary in vivo to extrinsic ATM-dependent suppressive factors and/or to a developmental defect. These transformed T cells may help to understand the distinct biological role of ATM in different cell types and to develop rational therapies for the immunological dysfunction of AT patients.

Published
2000

122. Conformational and biochemical differences in the TCR.CD3 complex of CD8(+) versus CD4(+) mature lymphocytes revealed in the absence of CD3gamma

Author

José R. Regueiro, Ester San José, Balbino Alarcón, Pilar S. Torres, B. Rubin, María L. Toribio, David A. Zapata, Almudena R. Ramiro, Laeticia Alibaud, and Alberto Pacheco-Castro

Subjects
CD4-Positive T-Lymphocytes, Time Factors, CD3 Complex, Transcription, Genetic, Protein Conformation, CD3, Receptors, Cell Surface, CD8-Positive T-Lymphocytes, Biochemistry, Herpesvirus 2, Saimiriine, Flow cytometry, Protein structure, medicine, Humans, Molecular Biology, medicine.diagnostic_test, biology, Reverse Transcriptase Polymerase Chain Reaction, T-cell receptor, Cell Biology, Blotting, Northern, Flow Cytometry, Precipitin, Precipitin Tests, Phenotype, Molecular biology, Receptor-CD3 Complex, Antigen, T-Cell, biology.protein, Calcium, Genes, T-Cell Receptor alpha, CD8, Intracellular
Abstract

Mature CD4(+) and CD8(+) T lymphocytes are believed to build and express essentially identical surface alphabeta T-cell receptor-CD3 (TCR.CD3) complexes. However, TCR.CD3 expression has been shown to be more impaired in CD8(+) cells than in CD4(+) cells when CD3gamma is absent in humans or mice. We have addressed this paradox by performing a detailed phenotypical and biochemical analysis of the TCR.CD3 complex in human CD3gamma-deficient CD8(+) and CD4(+) T cells. The results indicated that the membrane TCR.CD3 complex of CD8(+) T lymphocytes was conformationally different from that of CD4(+) lymphocytes in the absence of CD3gamma. In addition, CD8(+), but not CD4(+), CD3gamma-deficient T lymphocytes were shown to contain abnormally glycosylated TCRbeta proteins, together with a smaller, abnormal TCR chain (probably incompletely processed TCRalpha). These results suggest the existence of hitherto unrecognized biochemical differences between mature CD4(+) and CD8(+) T lymphocytes in the intracellular control of alphabetaTCR. CD3 assembly, maturation, or transport that are revealed when CD3gamma is absent. Such lineage-specific differences may be important in receptor-coreceptor interactions during antigen recognition.

124. Discovery of the fossil otter Enhydritherium terraenovae(Carnivora, Mammalia) in Mexico reconciles a palaeozoogeographic mystery

Author

Tseng, Z. Jack, Pacheco-Castro, Adolfo, Carranza-Castañeda, Oscar, Aranda-Gómez, José Jorge, Wang, Xiaoming, and Troncoso, Hilda

Abstract

The North American fossil otter Enhydritherium terraenovaeis thought to be partially convergent in ecological niche with the living sea otter Enhydra lutris, both having low-crowned crushing teeth and a close association with marine environments. Fossil records of Enhydritheriumare found in mostly marginal marine deposits in California and Florida; despite presence of very rich records of fossil terrestrial mammals in contemporaneous localities inland, no Enhydritheriumfossils are hitherto known in interior North America. Here we report the first occurrence of Enhydritheriumoutside of Florida and California, in a land-locked terrestrial mammal fauna of the upper Miocene deposits of Juchipila Basin, Zacatecas State, Mexico. This new occurrence of Enhydritheriumis at least 200 km from the modern Pacific coastline, and nearly 600 km from the Gulf of Mexico. Besides providing further evidence that Enhydritheriumwas not dependent on coastal marine environments as originally interpreted, this discovery leads us to propose a new east-to-west dispersal route between the Florida and California Enhydritheriumpopulations through central Mexico. The proximity of the fossil locality to nearby populations of modern neotropical otters Lontra longicaudissuggests that trans-Mexican freshwater corridors for vertebrate species in riparian habitats may have persisted for a prolonged period of time, pre-dating the Great American Biotic Interchange.

Published
2017
Full Text
View/download PDF

125. Análisis de factores de riesgos operacionales en programa institucional de farmacovigilancia de IPS Córdoba 2019

Author

Castilla Hernández, Miguel Ángel, Pacheco Castro, Miguel, and Amador Ahumada, Concepción Elena

Subjects
Adverse event, Pharmacovigilance, Public health, Farmacovigilancia, Risk factors, Salud pública, Evento adverso, Factores de riesgo
Abstract

Introduction. The Institutional Pharmacovigilance Program (PIFv) is a component of the National Pharmacovigilance Program (PNFv) executed by the Health Service Provider Institutions (IPS). Objective. Analyze the influence of operational risk factors in the PIFv of IPS with medium and high complexity pharmaceutical service in the Department of Córdoba in 2019. Methodology. Observational, cross-sectional study of association and quantitative approach; the population as well as the sample was formed by IPS with a medium and high complexity pharmaceutical service that were the subject of a technical assistance visit to the PIFv by the health section, to collect the information from the survey, the "HPE Software - PIFv" version 00 was designed with which the "HENRI PIFv Scale for the qualification of the implementation of the pharmacovigilance program in IPS" was automated; descriptive and inferential statistics were applied. Results. The technological tool consolidated the findings of each visit into a record, reducing the survey time by 50%. 13.8% of the IPS were of a public nature and 86.2% were from the private sector; 65.5% of the institutions studied classified the PIFv status as "not implemented", 31.1% as "in implementation" and 3.4% as "implemented"; 55.1% of the IPS presented 100% underreporting of Adverse Drug Event (ADE) in 2019; 31% of the IPS that received a technical assistance visit presented a status of the PIFv “not implemented” and underreporting of EAM of 100%; Inferential statistics did not identify significant statistical associations between the variables studied. Conclusion. In the human talent responsible for the PIFv it was observed that work itinerancy, work overload and / or a low training in pharmacovigilance can constitute operational risk factors for PIFv in the IPS studied, the same effect can produce the absence of a program of pharmacovigilance in the health section. CONTENIDO INTRODUCCION 23 1. OBJETIVOS 26 1.1 GENERAL 26 1.2 ESPECÍFICOS 26 2 MARCO REFERENCIAL 27 2.1 MARCO HISTÓRICO 28 2.1.1 Antecedentes histórico – legales 31 2.2 MARCO CONCEPTUAL 34 2.2.1 Instituciones Prestadoras de Servicios de Salud (IPS) 34 2.2.1.1 Naturaleza jurídica de las IPS 35 2.2.1.2 Ubicación geográfica de las IPS 35 2.2.1.3 Capacidad instalada de las IPS 36 2.2.2 Aspectos operacionales: Programa Institucional de Farmacovigilancia (PIFv) 37 2.2.2.1 Implementación del Programa Institucional de Farmacovigilancia (PIFv) 39 2.2.2.2 Evento Adverso a Medicamento (EAM) 39 2.2.3 Aspectos operacionales: Seguimiento al Programa Institucional de Farmacovigilancia (PIFv) 42 2.3 MARCO TEÓRICO 43 2.3.1 Gestión del riesgo: principios y fundamento 44 2.3.2 Prevención del Evento Adverso a Medicamentos (EAM), la gestión del riesgo y los procesos del servicio farmacéutico 45 2.3.3 El Programa Institucional de Farmacovigilancia (PIFv) y las medidas de mitigación del EAM en la IPS 48 2.3.4 Talento humano del Programa Institucional de Farmacovigilancia (PIFv) 50 2.4 MARCO LEGAL 51 2.5 MARCO DE ANTECEDENTES INVESTIGATIVOS 56 2.5.1 Antecedentes a nivel internacional 56 2.5.2 Antecedentes a nivel nacional 56 3 METODOLOGÍA 59 3.1 TIPO DE ESTUDIO 59 3.2 UNIDAD DE ANÁLISIS 59 3.3 SUJETO DE ESTUDIO 59 3.4 POBLACIÓN 60 3.5 MUESTRA 60 3.6 FUENTES DE INFORMACIÓN 60 3.7 PROCESO DEL ESTUDIO 62 3.8 MATERIALES Y MÉTODOS 63 3.9 CONTROL DE SESGOS DE INFORMACIÓN 66 3.10 PROCESOS ESTADÍSTICOS 67 3.11 PRESENTACIÓN DE LA INFORMACIÓN 67 3.12 ASPECTOS ÉTICOS 68 3.13 ASPECTOS DE PROPIEDAD INTELECTUAL Y DERECHOS DE AUTOR 69 3.14 ESTRATEGIAS DE SOCIALIZACIÓN 69 4 ANÁLISIS DE LOS RESULTADOS 70 4.1 AUTOMATIZACIÓN DE LA ENCUESTA HENRI - PIFv 70 4.2 CARACTERIZACIÓN DE IPS CON SERVICIO FARMACÉUTICO DE MEDIANA Y ALTA COMPLEJIDAD 72 4.2.1 Tipología de las IPS con servicio farmacéutico de mediana y alta complejidad 72 4.2.1.1 Clasificación según la distribución geográfica 72 4.2.1.2 Clasificación por ubicación geográfica 73 4.2.1.3 Clasificación por capacidad instalada 73 4.2.1.4 Clasificación por su naturaleza jurídica 74 4.2.1.5 Tipología de las IPS con servicio farmacéutico de mediana y alta complejidad en cuanto al estado del PIFv en el 2019 78 4.2.1.6 Tipología de las IPS con servicio farmacéutico de mediana y alta complejidad en cuanto al número de EAM reportados en el 2019 108 4.3 TIPIFICACIÓN DEL TALENTO HUMANO RESPONSABLE DEL PIFv EN LAS IPS CON SERVICIO FARMACÉUTICO DE MEDIANA Y ALTA COMPLEJIDAD Y DEL SEGUIMIENTO AL PIFv DE LA SECCIONAL DE SALUD 113 4.3.1 Tipología del talento humano responsable del PIFv en las IPS con servicio farmacéutico de mediana y alta complejidad – 2019 113 4.3.1.1 Contratación de químicos farmacéuticos en las IPS con servicio farmacéutico de mediana y alta complejidad 113 4.3.1.2 Contratación de un químico farmacéutico como referente de farmacovigilancia en la IPS con servicio farmacéutico de mediana y alta complejidad 116 4.3.2 Tipología del seguimiento al PIFv en la IPS con servicio farmacéutico de mediana y alta complejidad por la seccional de salud 2017 – 2019 120 4.4 RELACIONES ENTRE LAS CARACTERÍSTICAS DE LAS IPS CON SERVICIO FARMACÉUTICO DE MEDIANA Y ALTA COMPLEJIDAD Y LAS VARIABLES TALENTO HUMANO Y SEGUIMIENTO DE LA SECCIONAL DE SALUD AL PIFv 123 4.4.1 Relaciones entre el talento humano responsable del PIFv en las IPS con servicio farmacéutico de mediana y alta complejidad y el estado del PIFv 2019 123 4.4.2 Relaciones entre el cumplimiento del referente de farmacovigilancia en las IPS y el estado del PIFv 2019 136 4.4.3 Relaciones entre el talento humano responsable del PIFv en la IPS con servicio farmacéutico de mediana y alta complejidad y el reporte de EAM 2019 141 4.4.4 Relaciones entre las visitas de asistencia técnica a la IPS con servicio farmacéutico de mediana y alta complejidad y el estado del PIFv 145 4.4.5 Relaciones entre las visitas de asistencia técnica al PIFv de la IPS con servicio farmacéutico de mediana y alta complejidad y el reporte de EAM 151 4.5 ANÁLISIS DE LA INFLUENCIA DE FACTORES DE RIESGO OPERACIONALES EN EL PROGRAMA INSTITUCIONAL DE FARMACOVIGILANCIA (PIFV) 157 4.5.1 Itinerancia laboral del químico farmacéutico 158 4.5.2 Sobrecarga laboral del químico farmacéutico 161 4.5.3 Baja formación en farmacovigilancia del químico farmacéutico 162 4.5.4 Ausencia de Programa Departamental de Farmacovigilancia 162 5 DISCUSIÓN 166 CONCLUSIONES 175 RECOMENDACIONES 178 REFERENCIAS BIBLIOGRÁFICAS 181 ANEXOS 205 Introducción. El Programa Institucional de Farmacovigilancia (PIFv), es un componente del Programa Nacional de Farmacovigilancia ejecutado por las Instituciones Prestadoras de Servicios de Salud (IPS). Objetivo. Analizar la influencia de factores de riesgo operacional en el PIFv de las IPS con servicio farmacéutico de mediana y alta complejidad del Departamento de Córdoba en 2019. Metodología. Estudio observacional, transversal de asociación y enfoque cuantitativo; la población así como la muestra se formó por IPS con servicio farmacéutico de mediana y alta complejidad que fueron objeto de visita de asistencia técnica al PIFv por parte de la seccional de salud, para recoger la información de la encuesta se diseñó el “Software HPE – PIFv” versión 00 con que se automatizó la “Escala de HENRI PIFv para la calificación de la implementación del programa de farmacovigilancia en IPS”; se aplicaron estadísticas descriptiva e inferencial. Resultados. La herramienta tecnológica consolidó los hallazgos de cada visita en un acta disminuyendo el tiempo de encuesta en un 50%. El 13.8% de las IPS fueron de naturaleza pública y el 86.2% del sector privado; 65,5% de las instituciones estudiadas clasificaron con estado del PIFv “no implementado”, 31,1% “en implementación” y 3,4% como “implementado”; 55,1% de las IPS presentó subregistro del 100% de Evento Adverso por Medicamentos (EAM) en el 2019; el 31% de las IPS que recibió una visita de asistencia técnica presentó estado del PIFv “no implementado” y subregistro de EAM del 100%; la estadística inferencial no identificó asociaciones estadísticas significativas entre las variables estudiadas. Conclusión. En el talento humano responsable del PIFv se observó que la itinerancia laboral, la sobrecarga laboral y/o una baja formación en farmacovigilancia pueden constituirse en factores de riesgo operacional para el PIFv en las IPS estudiadas, igual efecto puede producir la ausencia de un programa de farmacovigilancia en la seccional de salud. Maestría Magíster en Salud Pública Trabajos de Investigación y/o Extensión

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results